ArticleNucleic acids research2026
Enriched methylomes of low-input and fragmented DNA using fragment ligation EXclusive methylation sequencing.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Adapting Clinical Chemistry Plasma as a Source for Liquid Biopsies.medRxiv : the preprint server for health sciences · 2026Article
Corrections and comments
- Update of
Authors and funding
14 authors.
Funding
Abstract
Epigenetic profiling is an emerging clinical tool for tumor profiling and liquid biopsies. Here, we developed Fragment Ligation EXclusive methylation sequencing (FLEXseq), a genome-wide methylation profiler that enriches and sequences the DNA fragments flanking CCGG motifs to cover a broad range of regulatory regions. FLEXseq strongly correlates with whole genome bisulfite sequencing (WGBS; Pearson's r = 0.97) yet requires only three- to seven-fold less sequencing depth than whole genome approaches to cover cell type-specific markers and 4- to 20-fold less sequencing to cover key regulatory regions like promoters. DNA dilutions down to 250 pg decreased CpG coverage, but bias in methylation remained low (Pearson's r ≥ 0.90). To demonstrate the broad applicability of FLEXseq, including highly fragmented DNA found in clinical specimens, we verified its usage across cells, body fluids, and formalin-fixed paraffin-embedded (FFPE) tissues. Across 106 cerebrospinal fluids, a specimen type challenged by low-input and fragmented DNA, FLEXseq enabled cell type deconvolution to distinguish between different tumor types and negative controls with an accuracy of 97%. FLEXseq offers a cost-efficient, single-nucleotide resolution approach to profile the methylome even with fragmented, low-input DNA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.